Lactobacillus brevis G-101 Decomposing MSG Into GABA
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Monosodium L-glutamate (MSG) consumption leads to adverse health effects such as MSG Symptom Complex, with existing technologies failing to effectively inhibit its absorption and address related health issues.
Innovation Solution
A Lactobacillus brevis G-101 strain is developed, capable of decomposing MSG into γ-aminobutyric acid (GABA), thereby inhibiting MSG absorption and providing anti-inflammatory benefits, which is used in various compositions and applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If MSG is used as a taste enhancer in food processing, then flavor enhancement is improved, but harmful effects on health (MSG Symptom Complex) worsen
Solution Approach 1:
The patent applies this principle by using Lactobacillus brevis G-101 to convert the harmful substance MSG into beneficial GABA through decomposition. The bacteria metabolize MSG in the digestive tract, transforming the harmful excitatory amino acid into gamma-aminobutyric acid, which has calming and protective effects on the nervous system, thereby converting a harmful substance into a beneficial one
Solution Approach 2:
The patent uses Lactobacillus brevis G-101 as an intermediary organism between MSG and the human body. This probiotic bacterium acts as a mediator that decomposes MSG before it can cause harmful effects, while simultaneously producing GABA as a beneficial byproduct. The intermediary bacteria thus protect the host from MSG toxicity while maintaining flavor benefits
2Adaptability or versatility
If existing technologies are used to address MSG absorption, then treatment options are limited, but effectiveness in inhibiting MSG absorption is insufficient
Solution Approach 1:
The patent applies self-service by utilizing the natural metabolic capabilities of Lactobacillus brevis G-101 to decompose MSG and produce GABA within the digestive tract. The probiotic bacteria perform the detoxification function autonomously through their inherent enzymatic systems, eliminating the need for external pharmacological interventions while providing reliable MSG absorption inhibition
Solution Approach 2:
The patent changes the biological parameter of the digestive tract by introducing Lactobacillus brevis G-101, which alters the metabolic environment. The bacteria modify the chemical composition by converting MSG to GABA, thereby changing the absorption characteristics and reducing harmful effects through biochemical parameter transformation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Lactobacillus brevis G-101 strain effectively reduces MSG absorption, converts MSG into GABA, and offers anti-inflammatory effects, effectively treating and preventing MSG Symptom Complex and inflammatory diseases.
Implementation Method 1
Lactobacillus brevis G-101 strain capable of decomposing monosodium L-glutamate
Implementation Method 2
Lactobacillus brevis G-101 strain... converting MSG into GABA
Data Source
AI summary
The present invention relates to a novel Lactobacillus brevis G-101 strain capable of decomposing monosodium L-glutamate (MSG), and a functional health food, a pharmaceutical composition, or a food product comprising the same as an active ingredient. More specifically, the strain is effective in reducing in vivo blood MSG levels of animals and attenuating MSG Symptom Complex, and thus can be used in a functional health food, a pharmaceutical composition, or a food product aiming to prevent in vivo absorption of MSG, which is known to be harmful, and improve the MSG Symptom Complex.